Journal of Huntington's Disease
September 17, 2026
Carsten Saft, Julia Jessen, David Kiefner et al.
Depression and suicidal ideation are common in Huntington's disease (HD). We report a 60-year-old male with HD who suffered from treatment-resistant depression with intermittent suicidal thoughts for 20 years, irritability and apathy. Despite multiple trials of antidepressants, no sustained improvement was achieved. Under nasal esketamine treatment his mood improved dramatically after three...
Fortschritte der Neurologie · Psychiatrie
June 8, 2026
Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.
Introduction: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). Historically, the development of EN resulted from the positive results of randomized clinical trials on the off-label use of subnarcotic ketamine infusions (SKI) for TRD. How effective, tolerable, and safe is off-label SKI compared to EN? Methods: Narrativ...
Psychopathology
2021
Naomi Lyons, Detlef E Dietrich, Johannes Graser et al.
3 citations
A disturbed sense of self is frequently discussed as an etiological factor for delusion symptoms in psychosis. Phenomenological approaches to psychopathology posit that lacking the sense that the self is localized within one's bodily boundaries (disembodiment) is one of the core features of the disturbed self in psychosis. The present study examines this idea by experimentally manipulating the...
Journal of Attention Disorders
April 1, 2017
Marc-Andreas Edel, Tanja Hölter, Kristina Wassink et al.
Objective: To compare a novel “third wave” mindfulness-based training program with an established skills training derived from dialectical behavior therapy, to reduce ADHD symptoms and improve mindfulness and self-efficacy. Method: Ninety-one adults with ADHD (combined and inattentive type, mainly medicated) were non-randomly assigned to and treated within a mindfulness-based training group...
European Psychiatry
July 17, 2016
Andreas Heinz, Martin Voss, Stephen M. Lawrie et al.
84 citations
BACKGROUND: First rank symptoms (FRS) of schizophrenia have been used for decades for diagnostic purposes. In the new version of the DSM-5, the American Psychiatric Association (APA) has abolished any further reference to FRS of schizophrenia and treats them like any other "criterion A" symptom (e.g. any kind of hallucination or delusion) with regard to their diagnostic implication. The ICD-10...
Schizophrenia Research
August 2012
Patrik Roser, Silke Lissek, Martin Tegenthoff et al.
Chronic cannabis use is associated with cognitive impairment and has been identified as a risk factor for schizophrenia. Patients with schizophrenia show profound deficits in social cognition such as the ability to attribute mental states to others, referred to as "theory of mind" (ToM). Aberrant activation of the ToM network has been demonstrated across different phases of schizophrenia,...
Pharmacopsychiatry
September 1, 2011
Patrik Roser, IS Haussleiter, HJ Chong et al.
2 citations
Preclinical and clinical research suggests that the endogenous cannabinoid system is involved in cognitive impairments related to schizophrenia. In particular, deficient generation of mismatch negativity (MMN) indicating auditory sensory memory is a characteristic finding in schizophrenic patients. Experimental studies implicate deficient N-methyl-D-aspartate (NMDA) receptor functioning in such...
Acta Psychiatrica Scandinavica
August 29, 2011
Sara Dragt, Dorien H. Nieman, Frauke Schultze-Lutter et al.
96 citations
Dragt S, Nieman DH, Schultze‐Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RKR, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Ruhrmann S, Klosterkötter J, Linszen DH, on behalf of the EPOS group. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Objective: Numerous studies...
Neuroscience Letters
May 27, 2011
Andreas M Stadelmann, Georg Juckel, Larissa Arning et al.
Numerous studies demonstrated a close relationship between cannabis abuse and schizophrenia with similar impairments in cognitive processing, particularly in P300 generation. Recently, an (AAT)n triplet repeat polymorphism within the cannabinoid receptor gene CNR1 has been found to be associated with both schizophrenia and substance dependence, and to modulate the P300 potential. As previously...
European Archives of Psychiatry and Clinical Neuroscience
September 2010
Patrik Roser, Beate Della, Christine Norra et al.
Mismatch negativity (MMN) is an auditory event-related potential indicating auditory sensory memory and information processing. The present study tested the hypothesis that chronic cannabis use is associated with deficient MMN generation. MMN was investigated in age- and gender-matched chronic cannabis users (n = 30) and nonuser controls (n = 30). The cannabis users were divided into two groups...
European Archives of Psychiatry and Clinical Neuroscience
August 2009
Patrik Roser, Jürgen Gallinat, Gordon Weinberg et al.
Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid...